These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34354860)

  • 1. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.
    Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC
    Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
    Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
    Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
    Parrish KE; Pokorny J; Mittapalli RK; Bakken K; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2015 Nov; 355(2):264-71. PubMed ID: 26354993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
    Talele S; Zhang W; Burgenske DM; Kim M; Mohammad AS; Dragojevic S; Gupta SK; Bindra RS; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2021 Dec; 379(3):343-357. PubMed ID: 34556535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood-Brain Barrier Permeability and Targets Glioblastoma.
    Cho CF; Farquhar CE; Fadzen CM; Scott B; Zhuang P; von Spreckelsen N; Loas A; Hartrampf N; Pentelute BL; Lawler SE
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
    Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
    Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
    [No Abstract]   [Full Text] [Related]  

  • 18. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
    Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
    Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
    Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors.
    Tsang JE; Urner LM; Kim G; Chow K; Baufeld L; Faull K; Cloughesy TF; Clark PM; Jung ME; Nathanson DA
    ACS Med Chem Lett; 2020 Oct; 11(10):1799-1809. PubMed ID: 33062157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.